Colin Howden, MD, discusses the mechanisms at work in vonoprazan as well as patient monitoring and potential future uses following a recent FDA approval for the treatment of erosive esophagitis.
Following the recent FDA approval for vonoprazan (Voquenza) in the treatment of gastroesophageal reflux disease, Colin Howden, MD, professor of medicine at the University of Tennessee Health Science Center, joined for an interview to discuss the inner workings of the drug, patient monitoring, and potential future uses.
Transcript
Can you explain the mechanism of action of vonoprazan and how it differs from other acid-blocking medications?
Vonoprazan belongs to a class of drugs called potassium-competitive acid blockers, often abbreviated P-CABs, and these are drugs that interact with the proton pump that hydrogen potassium ATPase to block the secretion of acid by parietal cells. P-CABS, including vonoprazan, bind in a non-covalent manner to the potassium-binding site of the proton pump, and they prevent the exchange of potassium ions for hydrogen ions. They work in a different mechanism from proton pump inhibitors because they're binding is ionic and non-covalent. Vonoprazan and other P-CABS do not require chemical conversion in the parietal cell before they are activated, unlike proton pump inhibitors. In comparison to proton pump inhibitors, vonoprazan starts to inhibit gastric acid secretion more rapidly and it produces a greater degree of suppression of gastric acidity that'll last for longer than conventional doses of proton pump inhibitors.
Are there steps health care providers should take to monitor and manage patients on vonoprazan therapy?
While there are no specific requirements or recommendations, if patients are receiving other drugs that may influence serum magnesium levels, notably diuretics, then there's a suggestion that they may want to check magnesium levels. But this is not a requirement.
Do you foresee any additional indications or developments for vonoprazan, or is it primarily intended for erosive esophagitis treatment?
Aside from erosive esophagitis, the Food and Drug Administration is also reviewing it for a possible indication of non-erosive reflux disease, sometimes referred to as NERD. As I said, that's currently under review by the Food and Drug Administration, and their decision will be offered by the middle of 2024.
This transcript has been lightly edited for clarity.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More